open access

Vol 70, No 2 (2019)
Original papers
Published online: 2018-12-10
Submitted: 2018-06-05
Accepted: 2018-10-30
Get Citation

Adropin in women with polycystic ovary syndrome

Justyna Kuliczkowska-Płaksej, Agata Mierzwicka, Maja Jończyk, Barbara Stachowska, Alina Urbanovych, Marek Bolanowski
DOI: 10.5603/EP.a2018.0092
·
Pubmed: 30480749
·
Endokrynologia Polska 2019;70(2):151-156.

open access

Vol 70, No 2 (2019)
Original papers
Published online: 2018-12-10
Submitted: 2018-06-05
Accepted: 2018-10-30

Abstract

Introduction: Women with polycystic ovary syndrome (PCOS) frequently develop metabolic complications. Among the newly found factors responsible for metabolic disorders, adropin seems to be of a great significance.

Material and methods: In total 134 women aged 17–45 years were enrolled. The PCOS group consisted of 73 women, diagnosed on the basis of Executive Committee of the European Society of Human Reproduction and Embryology — American Society for Reproductive Medicine (ESHRE-ASRM) criteria. All PCOS women presented phenotype A of PCOS. The control group consisted of 61 women with regular menstrual cycles, matched for nutritional status. All women underwent anamnesis, physical examination, anthropometric measurements, abdominal and transvaginal ultrasound, and dual-energy X-ray absorptiometry (DXA). Serum adropin levels were determined by ELISA. Biochemical [fasting glucose and insulin, oral glucose tolerance test, lipid and sex hormone-binding globulin (SHBG)] and hormonal (testosterone, androstenedione, luteinizing hormone, follicle-stimulating hormone and oestradiol) measurements were performed. Insulin resistance indices [(Homeostasis Model Assessment for Insulin Resistance (HOMA-IR), Quantitative Insulin Sensitivity Check Index (QUICKI), Matsuda] and free androgen index (FAI) were calculated according to the standard formula.

Results: Serum adropin levels were lower in the PCOS group (0.475 ± 0.200 vs. 0.541 ± 0.220, p = 0.069), but the results were not statistically significant. Positive correlations among adropin and androstenedione levels were observed in the PCOS group (r = 0.27, p = 0.025).

Conclusions: Women with PCOS have a different metabolic profile in comparison to women without this syndrome. We did not observe a statistically significant difference in adropin concentration between the PCOS and the healthy control group. Therefore, more studies regarding adropin in PCOS are needed. 

Abstract

Introduction: Women with polycystic ovary syndrome (PCOS) frequently develop metabolic complications. Among the newly found factors responsible for metabolic disorders, adropin seems to be of a great significance.

Material and methods: In total 134 women aged 17–45 years were enrolled. The PCOS group consisted of 73 women, diagnosed on the basis of Executive Committee of the European Society of Human Reproduction and Embryology — American Society for Reproductive Medicine (ESHRE-ASRM) criteria. All PCOS women presented phenotype A of PCOS. The control group consisted of 61 women with regular menstrual cycles, matched for nutritional status. All women underwent anamnesis, physical examination, anthropometric measurements, abdominal and transvaginal ultrasound, and dual-energy X-ray absorptiometry (DXA). Serum adropin levels were determined by ELISA. Biochemical [fasting glucose and insulin, oral glucose tolerance test, lipid and sex hormone-binding globulin (SHBG)] and hormonal (testosterone, androstenedione, luteinizing hormone, follicle-stimulating hormone and oestradiol) measurements were performed. Insulin resistance indices [(Homeostasis Model Assessment for Insulin Resistance (HOMA-IR), Quantitative Insulin Sensitivity Check Index (QUICKI), Matsuda] and free androgen index (FAI) were calculated according to the standard formula.

Results: Serum adropin levels were lower in the PCOS group (0.475 ± 0.200 vs. 0.541 ± 0.220, p = 0.069), but the results were not statistically significant. Positive correlations among adropin and androstenedione levels were observed in the PCOS group (r = 0.27, p = 0.025).

Conclusions: Women with PCOS have a different metabolic profile in comparison to women without this syndrome. We did not observe a statistically significant difference in adropin concentration between the PCOS and the healthy control group. Therefore, more studies regarding adropin in PCOS are needed. 

Get Citation

Keywords

adropin; polycystic ovary syndrome; metabolic syndrome

About this article
Title

Adropin in women with polycystic ovary syndrome

Journal

Endokrynologia Polska

Issue

Vol 70, No 2 (2019)

Pages

151-156

Published online

2018-12-10

DOI

10.5603/EP.a2018.0092

Pubmed

30480749

Bibliographic record

Endokrynologia Polska 2019;70(2):151-156.

Keywords

adropin
polycystic ovary syndrome
metabolic syndrome

Authors

Justyna Kuliczkowska-Płaksej
Agata Mierzwicka
Maja Jończyk
Barbara Stachowska
Alina Urbanovych
Marek Bolanowski

References (27)
  1. Setji TL, Brown AJ. Polycystic ovary syndrome: update on diagnosis and treatment. Am J Med. 2014; 127(10): 912–919.
  2. Pasquali R, Gambineri A. New perspectives on the definition and management of polycystic ovary syndrome. J Endocrinol Invest. 2018; 41(10): 1123–1135.
  3. Kumar KG, Trevaskis JL, Lam DD, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008; 8(6): 468–481.
  4. Ganesh Kumar K, Zhang J, Gao Su. Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring). 2012; 20(7): 1394–1402.
  5. Gao Su, McMillan RP, Zhu Q, et al. Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance. Mol Metab. 2015; 4(4): 310–324.
  6. Mierzwicka A, Bolanowski M. Nowe peptydy odgrywające rolę w zaburzeniach metabolicznych. Post Hig Med Dosw. 2016; 70: 881–886.
  7. Celik E, Yilmaz E, Celik O, et al. Maternal and fetal adropin levels in gestational diabetes mellitus. J Perinat Med. 2013; 41(4): 375–380.
  8. Wu L, Fang J, Chen L, et al. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med. 2014; 52(5): 751–758.
  9. Sayın O, Tokgöz Y, Arslan N. Investigation of adropin and leptin levels in pediatric obesity-related nonalcoholic fatty liver disease. J Pediatr Endocrinol Metab. 2014; 27(5–6): 479–484.
  10. Butler AA, Tam CS, Stanhope KL, et al. Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J Clin Endocrinol Metab. 2012; 97(10): 3783–3791.
  11. Kocaoglu C, Buyukinan M, Erdem SS, et al. Are obesity and metabolic syndrome associated with plasma adropin levels in children? J Pediatr Endocrinol Metab. 2015; 28(11-12): 1293–1297.
  12. Altincik A, Sayin O. Evaluation of the relationship between serum adropin levels and blood pressure in obese children. J Pediatr Endocrinol Metab. 2015; 28(9-10): 1095–1100.
  13. Yu Hy, Zhao P, Wu Mc, et al. Serum adropin levels are decreased in patients with acute myocardial infarction. Regul Pept. 2014; 190-191: 46–49.
  14. Yildirim B, Celik O, Aydin S. Adropin: a key component and potential gatekeeper of metabolic disturbances in policystic ovarian syndrome. Clin Exp Obstet Gynecol. 2014; 41(3): 310–312.
  15. Kume T, Calan M, Yilmaz O, et al. A possible connection between tumor necrosis factor alpha and adropin levels in polycystic ovary syndrome. J Endocrinol Invest. 2016; 39(7): 747–754.
  16. Inal ZO, Erdem S, Gederet Y, et al. The impact of serum adropin and ischemia modified albumin levels based on BMI in PCOS. Endokrynol Pol. 2018; 69(2): 135–141.
  17. Sen H, Erbag G, Bınnetoglu E, et al. Adropin levels in polycystic ovary syndrome patients. J Clin Anal Med. 2017; 8(1).
  18. Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012; 97(1): 28–38.e25.
  19. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19(1): 41–47.
  20. Apridonidze S, Essah PA, Iuorno MJ. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005; 90(4): 1929–1935.
  21. Behboudi-Gandevani S, Amiri M, Bidhendi Yarandi R, et al. The risk of metabolic syndrome in polycystic ovary syndrome: A systematic review and meta-analysis. Clin Endocrinol (Oxf). 2018; 88(2): 169–184.
  22. Aydin S, Kuloglu T, Aydin S, et al. Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes. Mol Cell Biochem. 2013; 380(1–2): 73–81.
  23. Akcilar R, Kocak FE, Simsek H, et al. Antidiabetic and hypolipidemic effects of adropinin streoptozotocin-induced type 2 diabetic rats. Bratisl Lek Listy. 2016; 117(2): 100–105.
  24. Beigi A, Shirzad N, Nikpour F, et al. Association between serum adropin levels and gestational diabetes mellitus; a case-control study. Gynecol Endocrinol. 2015; 31(12): 939–941.
  25. Aydin S, Kuloglu T, Aydin S. Copeptin, adropin and irisin concentrations in breast milk and plasma of healthy women and those with gestational diabetes mellitus. Peptides. 2013; 47: 66–70.
  26. Lian W, Gu X, Qin Y, et al. Elevated plasma levels of adropin in heart failure patients. Intern Med. 2011; 50(15): 1523–1527.
  27. St-Onge MP, Shechter A, Shlisky J, et al. Fasting plasma adropin concentrations correlate with fat consumption in human females. Obesity (Silver Spring). 2014; 22(4): 1056–1063.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl